0001179110-20-010439.txt : 20201013
0001179110-20-010439.hdr.sgml : 20201013
20201013191430
ACCESSION NUMBER: 0001179110-20-010439
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20201012
FILED AS OF DATE: 20201013
DATE AS OF CHANGE: 20201013
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kearney Terrence C
CENTRAL INDEX KEY: 0001289098
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36065
FILM NUMBER: 201237766
MAIL ADDRESS:
STREET 1: IN CARE OF HOSPIRA, INC.
STREET 2: 275 NORTH FIELD DRIVE
CITY: LAKE FOREST
STATE: IL
ZIP: 60045
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ACCELERON PHARMA INC
CENTRAL INDEX KEY: 0001280600
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 128 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-649-9200
MAIL ADDRESS:
STREET 1: 128 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
edgar.xml
FORM 4 -
X0306
4
2020-10-12
0
0001280600
ACCELERON PHARMA INC
XLRN
0001289098
Kearney Terrence C
128 SIDNEY STREET
CAMBRIDGE
MA
02139
1
0
0
0
Common Stock
2020-10-12
4
M
0
20000
28.37
A
25127
D
Common Stock
2020-10-12
4
M
0
10000
27.97
A
35127
D
Common Stock
2020-10-12
4
M
0
7500
30.17
A
42627
D
Common Stock
2020-10-12
4
S
0
2200
117.82
D
40427
D
Common Stock
2020-10-12
4
S
0
18177
119.11
D
22250
D
Common Stock
2020-10-12
4
S
0
16210
119.78
D
6040
D
Common Stock
2020-10-12
4
S
0
913
120.57
D
5127
D
Option to Purchase Common Stock
28.37
2020-10-12
4
M
0
20000
0
D
2024-07-14
Common Stock
20000
0
D
Option to Purchase Common Stock
27.97
2020-10-12
4
M
0
10000
0
D
2026-03-03
Common Stock
10000
0
D
Option to Purchase Common Stock
30.17
2020-10-12
4
M
0
7500
0
D
2027-03-02
Common Stock
7500
0
D
The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.29 to $118.08 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.50 to $119.49 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.50 to $120.48 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.50 to $120.70 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4.
The shares of common stock underlying this stock option award vested in equal quarterly installments over the first three years after the grant date.
The shares of common stock underlying this stock option award vested in full on the one year anniversary of the grant date.
Exhibit List: Exhibit 24 - Power of Attorney
/s/ Adam M. Veness, as attorney-in-fact for Terrence C. Kearney
2020-10-13
EX-24
2
kearneypoa.txt
Exhibit 24
POWER OF ATTORNEY
Know all by these presents, that the undersigned hereby constitutes and
appoints each of Kevin F. McLaughlin and Adam M. Veness, Esq., signing singly,
as the undersigned's true and lawful attorney-in-fact to:
(1) execute for and on behalf of the undersigned, in the
undersigned's capacity as an officer and/or director of
Acceleron Pharma Inc. (the "Company"), Forms 3, 4 and 5 in
accordance with Section 16(a) of the Securities Exchange Act
of 1934, as amended (the "Act"), and the rules thereunder;
(2) do and perform any and all acts for and on behalf of the
undersigned which may be necessary or desirable to complete
and execute any such Form 3, 4 or 5 and timely file such form
with the United States Securities and Exchange Commission and
any stock exchange or similar authority; and
(3) take any other action of any type whatsoever in connection
with the foregoing which, in the opinion of such
attorney-in-fact, may be of benefit to, in the best interest
of, or legally required by, the undersigned, it being
understood that the documents executed by such
attorney-in-fact on behalf of the undersigned pursuant to this
Power of Attorney shall be in such form and shall contain such
terms and conditions as such attorney-in-fact may approve in
such attorney-in-fact's discretion.
The undersigned hereby grants to each attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all the acts such attorney-in-fact shall
lawfully do or cause to be done by virtue of this power of attorney and the
rights and powers herein granted. The undersigned acknowledges that each of the
foregoing attorneys-in-fact, in serving in such capacity at the request of the
undersigned, is not assuming any of the undersigned's responsibilities to comply
with Section 16 of the Act.
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to each
of the foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of February 24, 2020.
By: /s/ Terrence C. Kearney
------------------------------------------------------
Print Name: Terrence C. Kearney
------------------------------------------------------